For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
In 2016, the European market for GERD drugs and devices have been accounted as the largest market worldwide, expected to grow with 0.93% CAGR during the forecasted period 2019-2027.
The chances of GERD among patients coming for diagnosis at least once per week is in the range of 8.8-25.9 % in Europe which demonstrates the presence of a large number of patients suffering from GERD in this region. Awareness about GERD and usage of self-medication is promoting the growth of the GERD drugs and devices market in Europe.
Germany and Spain are found to be the largest contributors to the European GERD drugs and devices market because of negative factors like a high share of out-of-pocket spending and inadequate numbers of health professionals are still enhancing the rate of GERD occurrence being untreated.
The key market players that are rigorously developing newer drugs and expanding their bases for individual market revenue increment are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.